Free Trial

Richard Law Analyst Performance

Analyst at The Goldman Sachs Group

Richard Law is a stock analyst at The Goldman Sachs Group in the medical sector, covering 9 publicly traded companies. Over the past year, Richard Law has issued 13 stock ratings, including buy, hold, and sell recommendations. While full access to Richard Law's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Richard Law's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
53.85% 7 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy53.8%7 ratings
Hold38.5%5 ratings
Sell7.7%1 ratings

Out of 13 total stock ratings issued by Richard Law at The Goldman Sachs Group, the majority (53.8%) have been Buy recommendations, followed by 38.5% Hold and 7.7% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
9 companies

Richard Law, an analyst at The Goldman Sachs Group, currently covers 9 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
100.0%

Richard Law of The Goldman Sachs Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
88.9%
MED - DRUGS
1 company
11.1%

Richard Law's Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
9/9/2025Boost Price Target$37.15$52.00Buy
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
8/7/2025Boost Price Target$16.57$30.00Buy
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
8/6/2025Boost Price Target$52.25$82.00Buy
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
7/25/2025Initiated Coverage$15.02$18.00Neutral
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
5/14/2025Lower Price Target$4.20$18.00Buy
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/9/2025Lower Price Target$7.00$13.00Neutral
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5/9/2025Lower Price Target$18.54$31.00Neutral
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
5/7/2025Lower Price Target$12.30$27.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4/8/2025Initiated Coverage$21.52$30.00Neutral
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
3/3/2025Lower Price Target$9.15$15.00Neutral
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2/13/2025Lower Price Target$10.36$24.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2/11/2025Initiated Coverage$4.92$6.00Sell
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1/17/2025Upgrade$41.47$82.00Buy